Alphabet Inc. Has $11.68 Million Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUE

Alphabet Inc. decreased its holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 49.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 744,948 shares of the company’s stock after selling 719,067 shares during the quarter. Monte Rosa Therapeutics accounts for 0.5% of Alphabet Inc.’s investment portfolio, making the stock its 15th biggest holding. Alphabet Inc.’s holdings in Monte Rosa Therapeutics were worth $11,681,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. GAMMA Investing LLC bought a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $30,000. Russell Investments Group Ltd. purchased a new position in Monte Rosa Therapeutics in the 3rd quarter valued at approximately $32,000. Lazard Asset Management LLC grew its stake in Monte Rosa Therapeutics by 42.9% in the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after buying an additional 3,262 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after buying an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares in the last quarter. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Price Performance

Shares of NASDAQ GLUE opened at $18.24 on Friday. The stock has a market cap of $1.54 billion, a PE ratio of -12.32 and a beta of 1.60. The firm has a fifty day moving average price of $18.54 and a 200-day moving average price of $18.41. Monte Rosa Therapeutics, Inc. has a 1 year low of $4.12 and a 1 year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. On average, research analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. JPMorgan Chase & Co. boosted their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Guggenheim reduced their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, insider Philip Nickson sold 5,845 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $17.69, for a total transaction of $103,398.05. Following the transaction, the insider owned 55,000 shares of the company’s stock, valued at approximately $972,950. This trade represents a 9.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jennifer Champoux sold 2,175 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the transaction, the chief operating officer directly owned 62,371 shares in the company, valued at $1,247,420. This trade represents a 3.37% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 6.40% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.